



Final Appraisal Recommendation

Advice No: 3616 – December 2016

Isavuconazole (Cresemba®) 100 mg hard capsules, 200 mg powder for concentrate for solution for infusion

Submission by Basilea Pharmaceutica International Ltd

Recommendation of AWMSG

Isavuconazole (Cresemba®) is recommended as an option for use within NHS Wales for the treatment of invasive aspergillosis in adults and the treatment of mucormycosis in adult patients for whom amphotericin B is inappropriate.

This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.

Additional note(s):

- AWMSG considered that isavuconazole (Cresemba®) satisfied the AWMSG criteria for orphan status.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2433), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	Basilea Pharmaceutica International Ltd
Date of first issue	December 2016
Last reviewed	September 2020

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 3616:
Isavuconazole (Cresemba®) 100 mg hard capsules, 200 mg powder for concentrate for solution for infusion
December 2016



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendations. Accreditation is valid for 5 years from October 2016. More information on accreditation can be viewed at <http://www.nice.org.uk/about/what-we-do/accreditation>